Last reviewed · How we verify
HY209
At a glance
| Generic name | HY209 |
|---|---|
| Also known as | HY209 gel, HY209-IV |
| Sponsor | Shaperon |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Phase 2 Trial of HY209gel in Atopic Dermatitis Patients (PHASE2)
- Evaluate Tolerability and Safety of HY209 in Healthy Volunteers (PHASE1)
- A Phase II Study of HY209 Gel for Atopic Dermatitis Patients (Shaperon) (PHASE2)
- A Phase I Study of HY209 Gel in Healthy Male Volunteers for Atopic Dermatitis (PHASE1)
- A Study of HY209 in Healthy Male Volunteers for Sepsis (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HY209 CI brief — competitive landscape report
- HY209 updates RSS · CI watch RSS
- Shaperon portfolio CI